{"groups":[{"description":"In Part 1, participants received pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year.","id":"FG000","title":"Pembrolizumab"},{"description":"In Part 1, participants received placebo IV as post-surgery therapy Q3W.","id":"FG001","title":"Placebo"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"514"},{"groupId":"FG001","numSubjects":"505"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"509"},{"groupId":"FG001","numSubjects":"502"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"41"},{"groupId":"FG001","numSubjects":"21"}],"type":"Continuing Part 1 Adjuvant Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"264"},{"groupId":"FG001","numSubjects":"280"}],"comment":"Completed Part 1 Adjuvant Therapy","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"250"},{"groupId":"FG001","numSubjects":"225"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"As of the 02-Oct-2017 interim database cut-off date, of the 1019 randomized participants in Part 1, 544 had completed Part 1 and 62 were continuing in Part 1. This interim results disclosure is for Part 1 only."}